Anavex Life Sciences
AVXL
About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Employees: 2
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
112% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 33
24% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $12M
12% more capital invested
Capital invested by funds: $270M [Q1] → $301M (+$31.9M) [Q2]
1.09% more ownership
Funds ownership: 36.93% [Q1] → 38.02% (+1.09%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
2% less funds holding
Funds holding: 181 [Q1] → 177 (-4) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
HC Wainwright & Co.
Raghuram Selvaraju
|
$42
|
Buy
Reiterated
|
10 Sep 2025 |
|
D. Boral Capital
Jason Kolbert
|
$46
|
Buy
Maintained
|
10 Sep 2025 |
Financial journalist opinion
Based on 4 articles about AVXL published over the past 30 days
